Moderna Stock

Moderna EBITDA per Employee

The EBITDA per Employee of Moderna (MRNA) as of Aug 3, 2026 is -3.70 M USD. In the previous year, EBITDA per Employee was -4.75 M USD — a change of -22.08% (higher).

EBITDA per Employee

-3.70 MUSD

YoY

-22.08%

Last updated:

EBITDA per Employee of Moderna is 2026 -3.70 M USD. EBITDA per Employee of Moderna was 2025 -4.75 M USD. It decreases by -22.08% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

EBITDA per Employee of Moderna is -3.70 M USD in 2026.

EBITDA per Employee of Moderna changed from -4.75 M USD to -3.70 M USD, representing a -22.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Moderna since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Moderna historically and in real time.

Access this data via the Eulerpool API

Workforce — Moderna

All Key Metrics — Moderna